Target intelligence / Profile preview

ATP-binding cassette sub-family D member 2 (ABCD2)

Target
ABCD2
Molecular classification
Transporter, ATP-binding cassette (ABC) transporter, Peroxisomal membrane protein
01

Overview

ATP-binding cassette sub-family D member 2 (ABCD2) is a peroxisomal membrane transporter protein and a member of the ATP-binding cassette (ABC) transporter superfamily[6][7]. It is a ‘half-transporter’ that forms functional homodimers (or in some contexts, heterodimers) to mediate the ATP-dependent import of specific long-chain and very long–chain fatty acyl-CoA substrates from the cytosol into the peroxisome, where these molecules are degraded through β-oxidation[2][5][8]. ABCD2 has a substrate profile that partially overlaps with, but is distinct from, its close homolog ABCD1; it is particularly effective for C22:0 and certain polyunsaturated fatty acids[2][5]. Mutations or dysregulation of ABCD2 have been implicated in severe peroxisomal disorders, notably adrenoleukodystrophy and Zellweger syndrome, where it may act as a modifier of disease severity[5][6]. Currently, no drugs directly target ABCD2, but it carries importance as a possible therapeutic target or modifier in treating peroxisomal lipid metabolism disorders[6][7].

Other names
ATP-binding cassette sub-family D member 2ABCD2Adrenoleukodystrophy-related proteinALDRALD1ALDL1ALDRPhALDRABC39Adrenoleukodystrophy-like 1
02

Mechanism of action

Facilitates ATP-dependent transport of fatty acyl-CoAs into peroxisomes for β-oxidation; hypothesized fatty acyl-CoA thioesterase and ATPase activities[5][7]

03

Biological functions

Peroxisomal import of long-chain and very long–chain fatty acyl-CoAsFatty acid β-oxidationPeroxisomal lipid metabolismDimerization with other half-transporters
04

Disease associations

Neurodegenerative diseaseAdrenoleukodystrophyZellweger syndromePeroxisomal biogenesis disordersMetabolic syndrome
05

Safety considerations

Potential metabolic disruptiondemyelinating neurological disease (with loss of function)overlapping effects with ABCD1 dysfunctionno major issues as a drug target owing to lack of approved modulators[5][6]
06

Interacting drugs

None established for direct modulation; experimental evidence may exist but not confirmed in clinical use[5][7]
07

Biomarkers

Mutations or expression level changes are candidate biomarkers in adrenoleukodystrophy and Zellweger syndrome[5][6]

Beyond the preview

Go deeper on ATP-binding cassette sub-family D member 2 (ABCD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-binding cassette sub-family D member 2 (ABCD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call